CSM Advisors LLC Takes $18.24 Million Position in Sanofi $SNY

CSM Advisors LLC purchased a new position in Sanofi (NASDAQ:SNY) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 386,534 shares of the company’s stock, valued at approximately $18,244,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mondrian Investment Partners LTD purchased a new position in Sanofi during the third quarter valued at approximately $171,742,000. Raymond James Financial Inc. lifted its holdings in Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after buying an additional 2,635,867 shares during the period. Thrivent Financial for Lutherans boosted its position in Sanofi by 10,152.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock valued at $103,846,000 after acquiring an additional 2,178,647 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Sanofi by 422.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock valued at $50,165,000 after acquiring an additional 859,246 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of Sanofi by 133.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,413,640 shares of the company’s stock valued at $66,681,000 after acquiring an additional 807,767 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Sanofi Stock Down 0.1%

Shares of SNY stock opened at $43.60 on Friday. The stock’s fifty day moving average price is $46.85 and its 200 day moving average price is $48.22. Sanofi has a 1-year low of $43.34 and a 1-year high of $59.17. The company has a market cap of $106.34 billion, a price-to-earnings ratio of 12.11, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73.

Analysts Set New Price Targets

SNY has been the subject of several recent research reports. HSBC reissued a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Wall Street Zen lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. UBS Group reiterated a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. Finally, TD Cowen restated a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.